Anzeige
Mehr »
Donnerstag, 04.09.2025 - Börsentäglich über 12.000 News
Set to Action: Q-Gold vor drastischer Neubewertung!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
110 Leser
Artikel bewerten:
(0)

Genhealth AI: GenHealth Creates 50M Public Patient Dataset

50 Million Medicare Patients. 10 Years. Unlimited Insights.

VIENNA, VIRGINIA / ACCESS Newswire / September 4, 2025 / Today, we at GenHealth (https://genhealth.ai) are introducing something that will transform healthcare data access and analytics: the G-Mode 50M Synthetic Patient Dataset (https://gmode.genhealth.ai/).

GenHealth.ai Wordmark

GenHealth.ai Wordmark

It's massive. We created a 50 million synthetic Medicare patients spanning over a decade of care from 2015 through 2025. Every detail is there: providers, facilities, prescriptions, procedures, costs, referrals, conditions, even the flow of care over time.

Obviously we can't make real patient data available, so we have generated all this data using our Large Medical Model trained on over 140M real de-identified patient claims histories**.**

Just like other generative AI models that can create new faces or images of people who don't exist, our Large Medical Model generates realistic patient journeys which preserve and help uncover nuanced relationships in healthcare data. Detailed, rich, and research-ready - but with no PHI, no identifiers, and zero privacy risk.

Fuel curiosity without barriers.

Traditionally, getting patient-level data is almost impossible. It's locked away, siloed, and restricted. Now, for the first time, anyone can explore healthcare at scale - from citizen scientists to the biggest research institutions.

  • Public health: Track disease patterns and model interventions.

  • Competitive Intelligence: Analyze competitor market share, pricing strategies, medical coding, and product positioning.

  • Education & research: Give students and data scientists a safe way to learn.

  • Quality and Cost: Identify opportunities to improve care quality while reducing costs.

  • Prior authorization: Test faster, more patient-friendly approaches for medical policies.

  • Fraud, waste, and abuse (FWA): Build and validate smarter detection algorithms.

Wrapped in a chatbot

Beyond just making the data available, we're providing effortless interaction. You don't need to know healthcare analytics, coding, or SQL to use it. We've wrapped the dataset in a chatbot interface.

That means you can just ask, in plain language:

  • "How many patients with diabetes were in the ER last year?"

  • "Which providers performed the most knee replacement surgeries from 2023 to 2025 for each county in Ohio?"

  • "What is the cost distribution for the total spend on care care for patients by year?"

  • What is the percentage of women 65 to 75 years of age who received osteoporosis screening in 2024?

And you'll get the answers. Instantly.

Built with our Large Medical Model

At the core is our Large Medical Model (LMM) - a transformer trained on over 140M patient records. It can both predict costs and risks as well as generate complete, realistic patient timelines from scratch. It's the same engine that powers our G-Mode Population Health Co-Pilot and AI-driven Prior Authorization tools. This is as real as fake can get. For example, our model can predict bee stings for patients in a random county of Pennsylvania at a similar rate to the real world 0.150% (real) vs 0.135% (G-Mode's synthetic data set).

A new era for healthcare data

This is the easiest, safest way ever to explore patient-level healthcare data. By making it as simple as having a conversation, we've opened the door wider than ever before.

For the lone citizen scientist. For the startup. For the biggest public health institutions.

We can't wait to see what you discover with G-Mode.

About GenHealth
GenHealth (https://genhealth.ai) is a healthcare technology company that uses AI to automate healthcare workflows, improve quality, and reduce costs. Our products include G-Mode for healthcare data exploration and the UMPA platform for automating medical necessity and prior authorization processes. We serve providers, health plans, and suppliers with HIPAA-compliant solutions that streamline data analytics and operations while maintaining high standards of care.

Contact Information
Mike Maseda
Head of Sales & Operations
marketing@genhealth.ai

.

SOURCE: Genhealth AI



View the original press release on ACCESS Newswire:
https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/genhealth-creates-50m-public-patient-dataset-1068555

© 2025 ACCESS Newswire
Solarbranche vor dem Mega-Comeback?
Lange galten Solaraktien als Liebling der Börse, dann kam der herbe Absturz: Zinsschock, Überkapazitäten aus China und ein Preisverfall, der selbst Marktführer wie SMA Solar, Enphase Energy oder SolarEdge massiv unter Druck setzte. Viele Anleger haben der Branche längst den Rücken gekehrt.

Doch genau das könnte jetzt die Chance sein!
Die Kombination aus KI-Explosion und Energiewende bringt die Branche zurück ins Rampenlicht:
  • Rechenzentren verschlingen Megawatt – Solarstrom bietet den günstigsten Preis je Kilowattstunde
  • Moderne Module liefern Wirkungsgrade wie Atomkraftwerke
  • hina bremst Preisdumping & pusht massiv den Ausbau
Gleichzeitig locken viele Solar-Aktien mit historischen Tiefstständen und massiven Short-Quoten, ein perfekter Nährboden für Kursrebound und Squeeze-Rally.

In unserem exklusiven Gratis-Report zeigen wir dir, welche 4 Solar-Aktien besonders vom Comeback profitieren dürften und warum jetzt der perfekte Zeitpunkt für einen Einstieg sein könnte.

Laden Sie jetzt den Spezialreport kostenlos herunter, bevor die Erholung am Markt beginnt!

Dieses Angebot gilt nur für kurze Zeit – also nicht zögern, jetzt sichern!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.